Syndax Pharmaceuticals (SNDX) and Royalty Pharma (RPRX) Enter $350M Royalty Funding Agreement for Niktimvo Nov 4, 2024 04:02PM
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ Nov 4, 2024 04:01PM
Arrowhead Pharmaceuticals (ARWR) Earns $50M Milestone from Royalty Pharma (RPRX) May 2, 2024 04:02PM
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma May 2, 2024 04:01PM
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) Aug 24, 2023 06:30AM


Aug 24, 2023 05:54AM Royalty Pharma plc (RPRX) and Ferring Pharmaceuticals Enter $500M Royalty Agreement for New Intravesical Gene Therapy Adstiladrin
Aug 24, 2023 01:15AM Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
Mar 23, 2023 07:00AM Royalty Pharma (RPRX) and PureTech Health (PRTC) Enter KarXT Royalty Agreement for Up to $500M
Mar 23, 2023 07:00AM Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
Mar 23, 2023 07:00AM Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
Mar 23, 2023 03:00AM PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:06AM Ionis Pharmaceuticals (IONS), Royalty Pharma (RPRX) enter into royalty agreement for up to $1.1 billion
Jan 9, 2023 09:05AM Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Dec 20, 2022 07:30AM Arrowhead (ARWR) Receives $25M Milestone Payment from Amgen (AMGN)
Dec 20, 2022 07:30AM Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Nov 9, 2022 08:11AM Arrowhead Pharmaceuticals (ARWR) Sells Royalty Interest in Olpasiran to Royalty Pharma (RPRX) for $250 Million and Future Milestones
Nov 9, 2022 08:10AM Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Aug 2, 2022 07:00AM Blueprint Medicines Reports Second Quarter 2022 Results
Jun 30, 2022 07:16AM Blueprint Medicines (BPMC) Enters $1.25B Strategic Financing Collaborations with Sixth Street and Royalty Pharma (RPRX)
Jun 30, 2022 07:15AM Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
Mar 29, 2022 08:00AM Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment
Jan 7, 2022 07:31AM Cytokinetics (CYTK) and Royalty Pharma (RPRX) Announce Funding Agreements Totaling up to $450 Million
Jan 7, 2022 07:30AM Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Sep 8, 2016 09:29AM Pre-Open Stock Movers 09/08: (RPRX) (RAD) (JUNO) Higher; (GEVO) (NLST) (TSCO) (PIR) Lower (more...)
Apr 13, 2016 09:33AM Pre-Open Stock Movers 04/13: (RPRX) (ACUR) (MDVN) Higher; (CLVS) (VRX) (S) Lower (more...)
Dec 26, 2014 10:10AM Repros Therapeutics (RPRX) Mentioned Positively at Markman Advisors